Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RPTX 
Repare Therapeutics Inc (RPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RPTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -71.73% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.36M USD | Price to earnings Ratio - | 1Y Target Price 5.33 |
Price to earnings Ratio - | 1Y Target Price 5.33 | ||
Volume (30-day avg) 203940 | Beta 0.87 | 52 Weeks Range 0.98 - 4.29 | Updated Date 04/1/2025 |
52 Weeks Range 0.98 - 4.29 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When - | Estimate -0.7933 | Actual -0.6779 |
Profitability
Profit Margin -158.37% | Operating Margin (TTM) -172.31% |
Management Effectiveness
Return on Assets (TTM) -26.76% | Return on Equity (TTM) -46.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -108946693 | Price to Sales(TTM) 0.81 |
Enterprise Value -108946693 | Price to Sales(TTM) 0.81 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.58 | Shares Outstanding 42510700 | Shares Floating 22306644 |
Shares Outstanding 42510700 | Shares Floating 22306644 | ||
Percent Insiders 0.98 | Percent Institutions 80.14 |
Analyst Ratings
Rating 4 | Target Price 6.75 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Repare Therapeutics Inc
Company Overview
History and Background
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing novel therapeutics targeting specific cancer vulnerabilities. Founded in 2016, the company leverages its proprietary discovery platforms, SNIPRx and STEP, to identify and develop targeted cancer therapies.
Core Business Areas
- Oncology Drug Discovery and Development: Repare Therapeutics focuses on discovering and developing cancer therapies by targeting specific vulnerabilities that can lead to breakthroughs in treatment and improved health outcomes.
Leadership and Structure
Repare Therapeutics has a leadership team with experience in drug discovery, clinical development, and commercialization. The company is structured around its research and development programs, with a focus on advancing its pipeline of targeted cancer therapies. Phillip W. Gutzman is the CEO.
Top Products and Market Share
Key Offerings
- Camonsertib (RP-6306): A potent and selective oral inhibitor of ATR (ataxia-telangiectasia and Rad3-related protein kinase) being developed for solid tumors with ATR pathway alterations. Phase 1/2 clinical trials are underway. Competitors include Vertex Pharmaceuticals (VXRT) and Merck (MRK).
- RP-1664: An oral selective PLK4 inhibitor in Phase 1 clinical trials. The company believes that RP-1664 has the potential to address unmet medical needs for patients with advanced solid tumors by disrupting centriole duplication, leading to mitotic arrest and tumor cell death. Competitors are limited due to the novelty of the target.
Market Dynamics
Industry Overview
The oncology therapeutics market is rapidly growing, driven by advancements in precision medicine, targeted therapies, and immuno-oncology. The market is competitive, with numerous companies developing novel cancer treatments.
Positioning
Repare Therapeutics is positioned as a precision oncology company focused on identifying and developing targeted therapies for specific cancer vulnerabilities. Its SNIPRx and STEP platforms provide a competitive advantage in identifying novel drug targets.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics is estimated to be in the hundreds of billions of dollars. Repare Therapeutics is targeting specific subsets of cancer patients with its therapies, positioning itself to capture a portion of this large market. Based on Phase II data, if Camonsertib gains approval, peak sales are expected to be at least $500 million per year.
Upturn SWOT Analysis
Strengths
- Proprietary discovery platforms (SNIPRx and STEP)
- Strong intellectual property portfolio
- Experienced management team
- Focus on precision oncology and targeted therapies
Weaknesses
- Clinical stage company with no approved products
- Reliance on successful clinical trial outcomes
- High research and development costs
- Dependence on partnerships for funding and development
Opportunities
- Potential for breakthrough therapies in targeted oncology
- Expansion of pipeline through internal discovery and external collaborations
- Increasing adoption of precision medicine in cancer treatment
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Vertex Pharmaceuticals (VRTX)
- Merck (MRK)
- Artios Pharma
Competitive Landscape
Repare Therapeutics' advantage lies in its novel targets and discovery platforms. However, it faces competition from larger, more established pharmaceutical companies with greater resources. Artios Pharma is a direct competitor for ATR inhibitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Repare Therapeutics has grown rapidly since its founding, driven by its innovative discovery platforms and promising clinical pipeline.
Future Projections: Analysts project significant revenue growth for Repare Therapeutics if its clinical programs are successful and its products are approved. Sales of RP-6306 are expected to be significant. Further data points require access to analyst estimates.
Recent Initiatives: Recent initiatives include advancing its clinical programs, expanding its discovery platforms, and securing partnerships with larger pharmaceutical companies.
Summary
Repare Therapeutics is a promising precision oncology company with innovative discovery platforms and a compelling clinical pipeline, but as a clinical-stage company, it faces inherent risks including clinical trial failures. The company has promising targets in areas with unmet need and is positioned for substantial growth if its programs are successful. The company will need to carefully manage its cash flow and partnerships to achieve its long-term goals.
Similar Companies
- VRTX
- MRK
- LLY
Sources and Disclaimers
Data Sources:
- Repare Therapeutics Inc. website
- Company SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated. Forward-looking statements are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repare Therapeutics Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2020-06-19 | President, CEO & Director Mr. Lloyd Mitchell Segal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://www.reparerx.com |
Full time employees 129 | Website https://www.reparerx.com | ||
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.